The Medicines Co

📅 Upcoming

🕒 Recent(90d)

News

• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 1d ago
• Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
  “The next 10 years of mycetoma care will determine whether it remains a story of neglect or becomes one of collective action,” writes Borna Nyaoke-Anoke.
  stat · 12d ago
• [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
  This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.
  biopharma_dive · 15d ago
• Compounders maintain a firm grip on the GLP-1 market
  Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
  biopharma_dive · 25d ago
• US drug shortages rise for third straight quarter, hurt by lone suppliers
  The number of drugs in shortage in the US rose for a third straight quarter, a situation complicated by the fact that almost half of the medicines in tight supply rely only on a single ...
  endpoints · 26d ago
• STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
  An Alzheimer’s drug from Biogen slowed cognitive decline in a mid-stage trial at roughly comparable rates as approved medicines
  stat · 27d ago
• Building a workforce engine for biomanufacturing
  Ohio’s $30M training initiative aims to scale talent pipelines and power life sciences growth statewide.
  fiercebiotech · 29d ago
• Opinion: I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule
  “American science is too valuable to be turned into a political football,” writes David J. Skorton, president of the Association of American Medical Colleges.
  stat · 2mo ago
• CVS obesity drug deal puts Lilly on equal footing with Novo
  The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
  biopharma_dive · 2mo ago
• Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
  A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
  biopharma_dive · 3mo ago